127 related articles for article (PubMed ID: 15778424)
1. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease.
Yan JH; Ataga K; Kaul S; Olson JS; Grasela DM; Gothelf S; Kutlar A; Orringer E
J Clin Pharmacol; 2005 Apr; 45(4):434-45. PubMed ID: 15778424
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.
de Montalembert M; Bachir D; Hulin A; Gimeno L; Mogenet A; Bresson JL; Macquin-Mavier I; Roudot-Thoraval F; Astier A; Galactéros F
Haematologica; 2006 Dec; 91(12):1685-8. PubMed ID: 17145606
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
6. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
8. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.
Small DS; Wrishko RE; Ernest CS; Ni L; Winters KJ; Farid NA; Li YG; Brandt JT; Salazar DE; Borel AG; Kles KA; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):585-94. PubMed ID: 19744014
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
Marbury T; Dowell JA; Seltzer E; Buckwalter M
J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
[TBL] [Abstract][Full Text] [Related]
10. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure.
Guasch A; Navarrete J; Nass K; Zayas CF
J Am Soc Nephrol; 2006 Aug; 17(8):2228-35. PubMed ID: 16837635
[TBL] [Abstract][Full Text] [Related]
11. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.
Tavakkoli F; Nahavandi M; Wyche MQ; Castro O
Clin Ther; 2005 Jul; 27(7):1083-8. PubMed ID: 16154487
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
Chaine B; Neonato MG; Girot R; Aractingi S
Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
Teichert J; Tuemmers T; Achenbach H; Preiss C; Hermann R; Ruus P; Preiss R
J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
[TBL] [Abstract][Full Text] [Related]
14. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
Fitzhugh CD; Wigfall DR; Ware RE
Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia.
Ulug P; Vasavda N; Kumar R; Keir L; Awogbade M; Cunningham J; Rees DC; Menzel S; Thein SL
Am J Hematol; 2008 Sep; 83(9):714-6. PubMed ID: 18615556
[TBL] [Abstract][Full Text] [Related]
16. Renal abnormalities in patients with sickle cell disease: a single center report from Saudi Arabia.
Aleem A
Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):194-9. PubMed ID: 18310866
[TBL] [Abstract][Full Text] [Related]
17. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
Makis AC; Hatzimichael EC; Kolios G; Bourantas KL
Haematologica; 2004 Mar; 89(3):360-1. PubMed ID: 15020278
[TBL] [Abstract][Full Text] [Related]
18. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males.
Berthaut I; Guignedoux G; Kirsch-Noir F; de Larouziere V; Ravel C; Bachir D; Galactéros F; Ancel PY; Kunstmann JM; Levy L; Jouannet P; Girot R; Mandelbaum J
Haematologica; 2008 Jul; 93(7):988-93. PubMed ID: 18508803
[TBL] [Abstract][Full Text] [Related]
19. The measurement of urinary hydroxyurea in sickle cell anaemia.
Dalton RN; Turner C; Dick M; Height SE; Awogbade M; Inusa B; Okpala I; O'Driscoll S; Thein SL; Rees DC
Br J Haematol; 2005 Jul; 130(1):138-44. PubMed ID: 15982356
[TBL] [Abstract][Full Text] [Related]
20. Proteinuria in children with sickle cell disease.
Marsenic O; Couloures KG; Wiley JM
Nephrol Dial Transplant; 2008 Feb; 23(2):715-20. PubMed ID: 18065783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
